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Sleep dysfunction is highly prevalent across the spectrum of neurodegenerative conditions and is a key determinant of quality
of life for both patients and their families. Mounting recent evidence also suggests that such dysfunction exacerbates cognitive
and affective clinical features of neurodegeneration, as well as disease progression through acceleration of pathogenic processes.
Effective assessment and treatment of sleep dysfunction in neurodegeneration is therefore of paramount importance; yet robust
therapeutic guidelines are lacking, owing in part to a historical paucity of effective treatments and trials. Here, we review the
common sleep abnormalities evident in neurodegenerative disease states and evaluate the latest evidence for traditional and
emerging interventions, both pharmacological and nonpharmacological. Interventions considered include conservative mea-
sures, targeted treatments of specific clinical sleep pathologies, established sedating and alerting agents, melatonin, and orexin
antagonists, as well as bright light therapy, behavioral measures, and slow-wave sleep augmentation techniques. We conclude by
providing a suggested framework for treatment based on contemporary evidence and highlight areas that may emerge as major
therapeutic advances in the near future.
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Introduction
Sleep dysfunction is prominent across the spectrum of neuro-
degenerative conditions, occurring in 40 to 0% of patients
[1–5]. It is a key determinant of patients’ quality of life [6],
falls risk [7], and progression to institutionalization [8–11], as
well as caregiver burden and health [12–14]. It should there-
fore be a priority in the clinical care of patients with neurode-
generative disease but is currently typically overlooked.
Moreover, mounting recent evidence contends that sleep
dysfunction contributes to the severity and progression of neu-
rodegeneration [15]. On a symptomatic level, it is well-
established that sleep deprivation and disruption leads to def-
icits in attention, executive function, and processing speed, as
well as promoting impulsivity, emotional lability, and depres-
sion [16–20]. Sleep abnormalities therefore almost certainly
contribute to the burden of such features common to neurode-
generative conditions. Importantly, however, exacerbation
may also occur at the level of the underlying pathogenic pro-
cesses. The discovery of the glymphatic pathway and its pre-
dominant activity during sleep [21–23], for example, has re-
vealed the critical role of sleep in the clearance of extracellular
neurotoxic waste linked to some forms of neurodegeneration.
Clearance of both β-amyloid and tau has been shown to occur
in this way [24, 25], and sleep deprivation has been shown to
effect marked, rapid increases in these pathogenic protein spe-
cies in both animal models [26, 27] and humans [28–30].
Likewise, sleep deprivation has been shown to promote tau
propagation [27] and induce neuroinflammation [31], both of
which have been implicated in neurodegenerative pathophys-
iology. Other recent studies have also revealed in detail the
role of sleep in memory consolidation through synaptic
modelling and the formation of cortical engrams [32–34].
Impairment of sleep is thus very likely to contribute to the
synaptic dysfunction and memory impairment characterizing
many neurodegenerative conditions.
Addressing sleep dysfunction in neurodegeneration is
therefore of critical importance, offering potential to not only
enhance quality of life for patients and their families, but also
to mitigate disease burden and delay progression. Given the
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lack of therapies that currently achieve this for neurodegener-
ative conditions, this potential is of paramount significance.
Here, we review the latest evidence for traditional and
emerging sleep therapies in neurodegeneration, both pharma-
cological and nonpharmacological. Reflecting the weight of
available literature, considered evidence relates predominant-
ly to Alzheimer’s and Parkinson’s disease, but, where avail-
able, is also discussed in relation to Huntington’s disease,
Lewy body dementia, and vascular dementia.
Sleep Dysfunction in Neurodegenerative
Conditions: Commonalities
and Discriminators
Important commonalities are present among neurodegenera-
tive conditions with regard to the nature of sleep dysfunction.
Insomnia, in the form of delayed sleep onset, fragmentation,
or early awakening difficulties, is a prevalent abnormality af-
fecting around 50% of patients [4] and is convergent across
the spectrum of neurodegenerative disease [4, 35, 36].
Circadian dysfunction is also common throughout, as evi-
denced by loss of robust rest–activity rhythms, abnormalities
of melatonin concentration and rhythmicity, and loss of auto-
nomic diurnal fluctuation [37, 38]. Likewise, where sleep ar-
chitecture is analyzed via polysomnography, a characteristic
pattern of abnormalities emerges, that of increased arousals/
awakenings, loss of slow-wave and rapid eye movement
(REM) sleep stages, increased latency to initiation of REM,
and consequent gain in time spent in the lightest stages of
sleep [35, 39–41]. It is also notable that, across the spectrum
of neurodegenerative disease, sleep abnormalities frequently
precede diagnostic clinical features: for example, sleep frag-
mentation precedes the onset of overt Alzheimer’s disease and
manifest Huntington’s disease [42, 43] and REM behavior
sleep disorder (RBD) often precedes the clinical onset of mo-
tor features of Parkinson’s, multiple system atrophy, or Lewy
body dementia [44, 45].
Nevertheless, important discriminators are also evident.
For example, obstructive sleep apnea (OSA) is notably prev-
alent in Alzheimer’s disease, affecting 40% of patients [46,
47], and is the predominant abnormality seen in vascular de-
mentia [48]. By contrast, restless leg syndrome (RLS) and
RBD are more prevalent in Parkinson’s disease, affecting 15
and 35 to 46% patients respectively [2, 5, 49], with rates of
RBD in multiple system atrophy and Lewy body dementia
being even higher [35]. While daytime sleepiness and
sundowning are prominent in Alzheimer’s disease, true exces-
sive daytime sleepiness and sleep attacks typify Parkinson’s
disease [5, 50]. Periodic limb movement disorder, meanwhile,
is seen more commonly in Huntington’s disease [51].
These parallels and discrepancies likely reflect the under-
lying pathology of neurodegeneration. Commonalities are
likely driven by shared neurodegenerative patterns of hypo-
thalamic involvement leading to circadian dysfunction, and
generalized atrophy leading to an inability to gate and support
sleep stages appropriately. By contrast, discriminators likely
reflect relative patterns of disease burden, for example, a
brainstem emphasis in Parkinson’s disease, versus basal fore-
brain dysfunction in Alzheimer’s [52].
Preliminary Therapeutic Considerations
It is vital that the process of addressing sleep dysfunction in a
patient with neurodegeneration begins with a comprehensive
assessment of the specific problems in question. For an excel-
lent recent review of appropriate questions, validated scales,
and objective investigations such as sleep studies and
actigraphy to aid in this process, please see the recent review
by Ooms and Ju [48]. This process will help ensure identifi-
cation of specific clinical sleep pathologies where present and
recognition of preliminary contributory factors to sleep dys-
function such as depression, pain, nocturia, medications, and
caffeine/nicotine/alcohol use. It is imperative that such ele-
ments are addressed first, prior to consideration of other
strategies.
Depression
Depression is highly prevalent in neurodegeneration [53], and
while the relationship between depression and sleep dysfunc-
tion is bidirectional, it is well recognized that depression fre-
quently leads to initiation and maintenance insomnia, as well
as sleep architectural disturbance including a loss of slow-
wave sleep [54]. Treating depression in Parkinson’s disease
has been associated with improvements in sleep symptoms
[55, 56]. Therefore, where depression and sleep dysfunction
are concomitant and the severity of depression mandates treat-
ment, it is prudent to consider such treatment prior to other
sleep interventions. However, attention should be paid to the
selection of antidepressant: selective serotonin reuptake inhib-
itors and venlafaxine can impair sleep quality, whereas agents
such as trazodone and mirtazapine promote sleep [54], and
antidepressants can exacerbate clinical sleep pathology
(Table 1).
Pain
Contributory pain, for example, due to comorbid osteoarthri-
tis, should be addressed with analgesics. Discomfort due to
rigidity/akinesia, dystonia, and impaired bed mobility in
Parkinson’s disease are commonly thought to contribute to
sleep dysfunction [60], such that dopaminergic therapy may
be of benefit [61]. However, some studies effecting specific
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improvement in these features have failed to show concomi-
tant improvement in sleep quality [62, 63].
Nocturia
Nocturia is a prominent cause of sleep disruption in
Parkinson’s disease, affecting around 35 to 66% of individuals
[5, 49], but is also a contributory factor in many patients with
other neurodegenerative conditions often secondary to age-
related comorbid conditions such as benign prostatic hyper-
trophy or heart failure. Simple measures such as the optimiza-
tion of timing of diuretics, reduction of water intake from late
afternoon, or convene catheter systems can therefore be of
significant benefit to many patients with disrupted sleep. In
the setting of Parkinson’s, optimization of dopaminergic ther-
apy may effect improvement in nocturia [64, 65], particularly
the nocturnal use of rotigotine patches [66]. Anticholinergic
interventions for nocturia, however, should be viewed with
caution due to their well-documented deleterious cognitive
side effects.
Influence of Medications for Comorbidities
The contribution of medications for comorbid conditions
should also be considered. For example, α-blockers, β-
blockers, corticosteroids, serotonin selective reuptake inhibi-
tors, and angiotensin-converting enzyme inhibitors all have
detrimental effects on sleep and should therefore be rational-
ized in the setting of sleep dysfunction.
Influence of Medications for Neurodegenerative
Conditions
The contribution of medications administered for the neuro-
degenerative condition itself should also be considered, espe-
cially with respect to timing and dose. For example, donepezil
and memantine administered for Alzheimer’s have been
shown to improve sleep quality overall [67, 68] but donepezil
may cause sleep disruption if taken late in the day [69]; mod-
ification of timing may therefore bring benefit. Likewise, do-
pamine agonists improve sleep quality and daytime function-
ing in Parkinson’s [70, 71] but carry a dose-related risk of
excessive daytime somnolence and sleep attacks; therefore,
dosing should be reviewed in the setting of sleep dysfunction.
Caffeine, Nicotine, and Alcohol Exposure
Exposure to caffeine, alcohol, or nicotine less than 4 h prior to
going to bed is associated with poor sleep quality; patients’
use of such items should therefore also be reviewed and ad-
dressed. Particular effort should be made to probe alcohol use
accurately, as 26% of elderly individuals with sleep problems
have reported self-medicating with alcohol for sleep induction
[72], and alcohol abuse is frequent in neurodegenerative con-
ditions that promote addictive behaviors/impulse control
disorders.
Treatment of Clinical Sleep Pathology
Alongside such considerations, clinical sleep pathology such
as OSA, RLS, PLMD, or RBD should be addressed in a
targeted way where present. This is vital, as such factors make
a significant contribution to overall sleep dysfunction: for ex-
ample, RLS frequently leads to sleep onset insomnia, and
OSA and PLMD may contribute to sleep fragmentation and
daytime sleepiness [73, 74]. This is also important as highly
effective interventions are available: for example, continuous
positive airway pressure (CPAP) for OSA has been shown not
only to improve sleep quality, but also to enhance mood and
cognition, and slow cognitive decline in Alzheimer’s disease
[75–78]. The treatment of such pathology has been recently
reviewed in detail elsewhere [49], but a framework of key
strategies is provided in Table 1.
Where such interventions are unsuccessful in effecting suf-
ficient improvement in sleep dysfunction, further pharmaco-
logical and nonpharmacological strategies should be consid-
ered. Herein we evaluate current evidence in these two
domains.
Table 1 Key considerations in addressing clinical sleep pathology






















1. Exclude iron/B12 deficiency






























3. Clonazepam (except in
presence of cognitive
impairment/OSA)
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Pharmacological Therapies
Sedating and Alerting Agents
A number of hypnotic agents, including benzodiazepines, Z-
drugs, and sedating antidepressants and antihistamines, are
frequently used to treat insomnia in healthy adults.
However, such agents are almost exclusively only approved
for short-term use and are recommended as a secondary mea-
sure to nonpharmacological approaches. This is because i) all
such agents bear limited efficacy and salient risk of significant
adverse effects and ii) there is insufficient evidence to balance
benefits against such risks for long-term use in healthy adults
[79]. There is even less scope to contend that benefits out-
weigh such risks in older individuals or patients with neuro-
degenerative disorders: as outlined below, robust randomized
controlled trials are sparse, and extrapolation from observa-
tional studies suggests that risks are likely to be more promi-
nent in such populations.
Benzodiazepines and Z-Drugs
Both benzodiazepines, such as temazepam, nitrazepam, and
triazolam, and Z-drugs, such as zopiclone, zolpidem, and
zaleplon, improve sleep quality by reducing sleep latency
and awakenings via agonism of GABAA receptors, the main
inhibitory neurotransmitter receptors in the brain. Adverse
effects of benzodiazepines include tolerance, dependence,
and withdrawal, as well as both acute [80, 81] and chronic
[82] impairment of attention and psychomotor speed.
Impairment of memory consolidation is also well supported,
although refuted by some studies [83–85]. While risks of such
adverse effects are lower with Z-drugs, they are not absent
[86, 87]. Moreover, both benzodiazepines and Z-drugs have
been found to reduce REM and/or slow-wave sleep [88–90],
stages of sleep vital to memory consolidation [32–34] and
glymphatic clearance of neurotoxic waste [21].
In line with these observations, among elderly populations,
benzodiazepines and Z-drugs are consistently associated with
an increased risk of hip fracture due to falls [91], and some
evidence suggests an increased risk of cognitive impairment
[92] and decline [93]. Likewise, in an observational study in a
probable Alzheimer’s cohort adjusted for baseline cognitive
function and confounding clinical features [94], use of benzo-
diazepines was associated with a higher risk of deterioration.
In Parkinson’s disease, a small placebo-controlled study of
eszopiclone identified improved subjective sleep measures
without marked adverse events [55], but with a treatment pe-
riod of only 6 weeks. High-quality evidence among
neurodegeneration-specific cohorts is otherwise lacking.
Thus, it is highly likely that use of such agents in a neuro-
degenerative population will bring harm in excess of benefit
and should therefore be viewed with caution.
Sedating Antihistamines and Antidepressants
Sedating antihistamines such as diphenhydramine and hy-
droxyzine are some of the most frequently used agents in
individuals with insomnia, in part due to their availability in
over-the-counter preparations. However, the mixed
antihistamine/anticholinergic effect of such agents can cause
prominent sedation, cognitive impairment, delirium, and in-
creased daytime somnolence, such that avoidance is recom-
mended in a neurodegenerative population [95–97].
Sedating antidepressants, such as amitryptiline, trazodone,
mirtazapine, and doxepin, are also commonly used in the
treatment of insomnia. Of note, trazodone has shown neuro-
protective effects and rescue of memory deficits in preclinical
models of neurodegeneration [98]. However, the majority of
such antidepressants bear the same potential for deleterious
outcomes as antihistamines, due to mixed anticholinergic
and/or antihistamine effects. In line with this, observational
studies in older individuals have identified the use of such
agents as associated with increased risk of both hip fracture
[99] and mortality [100]. A small blinded placebo-controlled
trial of trazodone in an Alzheimer’s disease cohort found an
improvement in total sleep time without prominent adverse
events or cognitive impairment [101]. However, the treatment
period was only for 2 weeks; this finding has not been repli-
cated in other studies, some of which and, indeed, a number of
other studies have identified trazodone as bearing prominent
risks of cognitive impairment [102] and adverse outcomes
[100]. Alongside this, a randomized controlled trial of
mirtazapine in Alzheimer’s has found no benefit to sleep or
cognitive outcomes, with an increase in daytime drowsiness
[103]. It is therefore recommended that such agents are
avoided for sleep therapy except where depression is concom-
itant and requires pharmacological intervention. Nevertheless,
some more favorable evidence is present for doxepin: a 12-
week double-blind controlled study in elderly individuals with
chronic primary insomnia identified objective sleep benefit
without prominent adverse effects [104], and an open-label
study in a Parkinson’s cohort identified improved cognitive
and subjective sleep outcomes without major adverse effect
[105], although the treatment period was only 6 weeks. Again,
however, these findings have yet to be replicated or trialled in
larger cohorts, and as such this evidence has to be seen to be as
inconclusive at this stage.
Antipsychotics
Antipsychotics represent a further class of agents that have
been used in the treatment of sleep dysfunction in neurode-
generation, typically capitalizing upon their hypnotic effect
when administered for behavioral and psychological symp-
toms of dementia (BPSD). Short-term randomized studies
have supported their ability to significantly increase total sleep
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time in patients with dementia [106], and a 5-year observa-
tional study in Alzheimer’s disease comparing outcomes from
risperidone versus zolpidem, melatonin, or no treatment found
superior outcomes within the risperidone subgroup [107].
However, this is contradicted by the appropriately adjusted
observational study conducted by Ellul et al. [94], in which
antipsychotics were associated with greater deterioration in
patients with Alzheimer’s, and is at odds with a weight of
evidence suggesting that antipsychotics carry an increased risk
of hip fracture [99], cognitive decline, cerebrovascular acci-
dent, and death [99, 108–110] among patients with dementia.
It is therefore not recommended that such agents are used to
address sleep dysfunction, unless they already mandated for
concomitant BPSD. Where this is needed, there is some evi-
dence to suggest that quetiapine carries a lower risk of adverse
effects than other antipsychotics, but this is tempered by con-
current lower efficacy for treating BPSD [111].
Sodium Oxybate
Sodium oxybate, an agent used in the treatment of narcolepsy
and thought to act via GABAergic mechanisms, is attracting
growing interest as a possible alternative pharmacological
agent for the treatment of sleep dysfunction in neurodegener-
ation. Not only has it been found to enhance slow-wave ac-
tivity and counteract the cognitive effects of sleep deprivation
in healthy adults [112], it has also shown promising effects on
toxic proteinopathies, neuroprotection, and neuroinflamma-
tion in animal models of neurodegeneration [113].
Moreover, in Parkinson’s disease, both open-label [114] and
small randomized controlled trials [115] have identified both
subjective and objective sleep improvement following its use.
Nonetheless, de novo sleep apnea or parasomnia was induced
in 3/12 participants [115], long-term use in a neurodegenera-
tive cohort has yet to be assessed, and its proposed
GABAergic mode of action raises the potential that this agent
will have similar problems to those seen with benzodiazepines
and Z-drugs.
Modafinil
Some studies have considered the converse approach to ad-
dressing sleep dysfunction in neurodegeneration, by adminis-
tering the alerting agent modafinil during waking hours.
However, evidence to date has not supported its use:
modafinil has failed to show consistent benefit for fatigue
[116] or daytime somnolence [114, 117, 118] in Parkinson’s
disease or for apathy in Alzheimer’s disease [119]. A small
randomized controlled acute single-dose trial in Huntington’s
disease identified some improvement in alertness, but with no
improvement tomood, and deleterious cognitive effects [120].
Melatonin
Melatonin, the hormone that helps orchestrate circadian
sleep–wake function, has received considerable research in-
terest as a further alternative pharmacological agent for the
treatment of sleep dysfunction in neurodegeneration.
Exogenous melatonin administration can influence both circa-
dian rhythm and sleep quality [121], and the reduction in
release of endogenous melatonin across the spectrum of neu-
rodegeneration [37] would suggest that administration may
have a beneficial normalizing effect. Moreover, preclinical
studies have suggested that melatonin could have an indepen-
dent antioxidant, anti-inflammatory, and neuroprotective role
[122], and one of promoting glymphatic clearance [123] of
neurotoxic waste.
However, while a number of studies have suggested a ben-
efit of melatonin therapy in Alzheimer’s disease, the great
majority of these are open-label studies and based on subjec-
tive outcomes [124–127]. Of the five robust randomized con-
trolled trials in Alzheimer’s disease employing objective out-
comes based on actigraphic sleep variables, the evidence is
inconclusive. Three have failed to show benefit to any sleep
variable [128–130], while two have demonstrated mixed ben-
efit: Asayama et al. [131] reported a significant increase in
total sleep time (mean, 103 min) with decreased nocturnal
activity, while Dowling at al. [132] reported improved rest–
activity rhythm, but only through improvements in wake ac-
tivity rather than sleep, and only when administered in con-
junction with light therapy. This lack of consensus may relate
to the wide range of melatonin doses employed in these stud-
ies. The cognitive benefit of melatonin therapy in Alzheimer’s
disease has been reported in two studies [131, 133] but the
extent of this is of questionable clinical significance: a change
of 1.5 out of a total of 30 points on the Mini-Mental State
Examination (MMSE) and 3.5 to 4.3 out of a scale of 70
points on the Alzheimer’s Disease Cognitive Assessment
Scale (ADAS-Cog).
Only one robust study of melatonin therapy has been un-
dertaken in mild cognitive impairment. This double-blind pla-
cebo cross-over study [134] suggested improvement in both
sleep quality and rest–activity rhythms as reported by
actigraphy outcomes, as well as benefits to depression and
cognition, but to our knowledge this finding has not been
reproduced in any other study to date.
Very limited high-quality data is available as to the value of
melatonin therapy in Parkinson’s disease. Of studies available
in English, there has been one placebo-controlled trial with
actigraphic outcomes [135] which demonstrated no benefit
other than a gain of just 10 min of total sleep time, while a
randomized double-blind placebo-controlled trial showed no
benefit on objective polysomnographic outcomes and no ben-
efit to motor symptoms [136]. However, a recent evidence-
based review [137] has found melatonin to be “possibly
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useful” in the treatment of insomnia in Parkinson’s, on the
basis of i) positive studies employing subjective sleep out-
comes and ii) melatonin’s low side effect profile.
Overall, meta-analyses evaluating the effect of melatonin
on Alzheimer’s, Parkinson’s, or mixed dementia have found
no benefit to any sleep or cognitive variable [138, 139], other
than two reporting a modest, likely clinically insignificant
increase in total sleep time: 24 min [140] and 33 min [141].
However, these findings should not be conflated with those
pertaining to RBD, where there is a strong evidence base for
the efficacy of melatonin: open-label prospective [57, 59],
retrospective [58], and double-blind placebo-controlled
[142] studies have all suggested significant scope for melato-
nin therapy to reduce RBD episodes, as confirmed by poly-
somnographic outcomes.
Orexin Antagonists
Orexin, also known as hypocretin, is a key hypothalamic neu-
ropeptide regulating sleep by promoting wakefulness and
arousal. The recent development of pharmacological orexin
antagonists for clinical use therefore represents an emerging
avenue of sleep therapy bearing potential in neurodegenera-
tion [52, 143]. In addition, preclinical studies in mice have
suggested that orexin antagonism can also suppress β-
amyloid accumulation [144].
Two phase 3 trials of orexin antagonists [145, 146] have
produced moderately promising results in the treatment of
primary insomnia, increasing total sleep time (55 min treat-
ment group vs 19 min placebo group) and reducing wake time
after sleep onset (48 min treatment group vs 25 min placebo)
by reducing the duration of wakeful periods. Moreover, head
to head trials of orexin antagonists versus zolpidem have sug-
gested superiority with respect to latency to persistent sleep
and sleep maintenance [147] and also to cognitive outcomes
[148]. Levels of somnolence appear comparable [149] and, if
present, are mild–moderate and rarely require drug withdraw-
al [145, 146]. Sleep architecture also appears largely unaffect-
ed [145].
Encouragingly, studies involving older healthy participants
have not demonstrated significantly different efficacy or safe-
ty outcomes [145, 150], and the sole trial in a neurodegener-
ative cohort that has been published to date has suggested
strikingly similar outcomes to those in healthy cohorts. In this
randomized controlled trial undertaken in patients with insom-
nia and mild–moderate Alzheimer’s [151], orexin antagonism
was superior to placebo with respect to improvements in total
sleep time (73 min vs 45 min) and wake time after sleep onset
(− 45 min vs – 29 min), with no major effect on sleep archi-
tecture. Moreover, limited cognitive assessment through the
Mini Mental State Examination and Symbol Digit Task did
not suggest deleterious cognitive outcomes, somnolence was
not prominent or severe, and while there were more falls in the
treatment group (2.1% vs 0%), these were not judged to be
drug related.
Nonetheless, the efficacy and safety of orexin antagonists
in neurodegeneration remains to be tested robustly. Indeed,
the fact that orexin levels are reduced in many neurodegener-
ative conditions [152, 153] may predict poor outcomes, and
the central activity of orexin antagonists raises the potential for
adverse events in such populations. In particular, the phase 3
studies were undertaken in cohorts that excluded depression.
Given the high rates of coincidence of depression and sleep
dysfunction in neurodegenerative conditions, assumptions
cannot yet be extrapolated regarding safety for affective out-
comes. It is also of note that, to date, orexin antagonists are
only approved for clinical use in Japan, Australia, and the
USA.
Nonpharmacological Interventions
Nonpharmacological sleep therapies, most notably bright light
therapy and behavioral interventions, alsomerit consideration.
Bright Light Therapy
Light is the most powerful zeitgeber of the human circadian
system [154], and bright light therapy delivered by light emit-
ters (e.g., lightboxes) is known to affect both circadian rhythm
[155, 156] and sleep quality [157] in healthy individuals.
There is also a strong evidence base for its efficacy in depres-
sion [158]. The potential for bright light therapy to treat sleep
dysfunction and its corollaries in neurodegeneration has there-
fore received considerable research attention.
The majority of studies with objective actigraphic sleep
outcomes have been undertaken in mixed dementia cohorts
in residential settings. Most have demonstrated a degree of
benefit; many in the absence of a control arm raising the pos-
sibility of placebo effects [159–161], but gains have also ex-
tended to controlled studies [162–164]. The most common
benefit has been of strengthened circadian rhythm [159, 160,
164, 165], but some studies have also demonstrated enhanced
total sleep time and sleep efficiency [159, 161] and reduced
wake after sleep onset [161]. Five studies have also analyzed
cognitive outcomes [166–170]. Each demonstrated minor
benefit, but outcomes were limited to Mini-Mental State
Examination (MMSE) only and may have been consequent
to the alerting influence of bright light rather than via changes
in sleep quality. Evidence regarding the effect on behavioral
features of neurodegeneration is mixed: while some studies
have reported improvements in both depression and agitation
alongside sleep benefit [159, 166], others have demonstrated
exacerbated agitation [171].
With respect to studies in specific dementia subtypes, stud-
ies of bright light therapy in Alzheimer’s-only cohorts have
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demonstrated similar benefits to those in mixed dementia
studies [163], while a head-to-head study of vascular dementia
versusAlzheimer’s disease favored a greater benefit in vascu-
lar dementia [162]. Uncontrolled, unblinded studies in
Parkinson’s disease have suggested benefit of bright light
therapy to mood, motor outcomes, and subjective markers of
sleep [172, 173]. However, controlled studies have found fre-
quent parallel sleep outcomes between active and control con-
ditions [174, 175], raising the possibility of a placebo effect.
Despite this overall positive potential, meta-analyses of
bright light therapy in neurodegeneration have largely failed
to recommend its use overall. While the benefits seen in most
studies are acknowledged, these have been insufficient to con-
tend significant efficacy overall [176–178]. Onemeta-analysis
has advocated its use [179], but estimates a weak effect size
(Hedges g = 0.3). This outcome likely relates to the same fac-
tors that limit the practical suitability of bright light therapy for
patients with neurodegenerative conditions: to be both effec-
tive and comparable between studies, bright light therapy re-
quires consistent daily use, at a consistent time tailored to the
patient’s circadian rhythm, at a consistent sedentary distance
to achieve uniform lux exposure, and in a season/setting
where effects are not outweighed by environmental light ex-
posure [166]. This is clearly not always feasible for patients
with dementia; indeed, studies incorporating adherence anal-
ysis have reported noncompliance to be as high as 25% (155;
Lazar personal communication). The development of blue
light glasses [180] may circumvent some of these barriers,
but have yet to be tested robustly.
Behavioral Measures
Behavioral measures, collectively known as cognitive behav-
ioral therapy for insomnia (CBT-I) and summarized in
Table 2, have a strong evidence base in improving sleep qual-
ity in healthy individuals [181].
Studies of the use of such measures in neurodegeneration
have been encouraging. As for bright light therapy, the major-
ity of evidence comes from mixed dementia cohorts, most
using multicomponent techniques focusing on sleep hygiene.
Almost all studies have suggested benefit, many in enhanced
daytime wakefulness [182, 183], but also in reduced wake
time at night [184] and sleep duration [185], confirmed both
by actigraphy [182–185] and polysomnography [186, 187].
Some studies have also reported associated cognitive benefit
[186] and a reduction in agitation [185, 188].
Moreover, such findings extend to Alzheimer’s specific
cohorts, where both sleep hygiene alone [189] and in combi-
nation with light therapy [190, 191] have been shown to ben-
efit sleep quality. Similarly, CBT-I has been shown to benefit
sleep quality and executive function in mild cognitive impair-
ment [192]. Akin to bright light therapy, there is a relative
paucity of high-quality studies in Parkinson’s specific cohorts,
with most studies employing subjective outcomes suggesting
benefit [193–195], whereas objective measures have tended to
be negative [105, 196]. Nonetheless, daytime physical exer-
cise has been found to improve nocturnal actigraphy [197] and
polysomnographic outcomes [198] in Parkinson’s.
As with bright light therapy, the application of such mea-
sures is clearly contingent upon an individual patient and/or
carer’s ability to implement/engage with them consistently,
which may be impractical for many patients. Adherence is
key to efficacy [191], and attrition rates have been as high as
40% in community studies [199]. Furthermore, in the main,
carers have been found to need tailored and patient-specific
advice rather than generic guidance [200], which may limit
feasibility.
A combined recent meta-analysis [176] of bright light ther-
apy and behavioral measures in the treatment of sleep dys-
function in neurodegeneration has reported benefit to sleep
efficiency, but only when used in combination. However, no
overall benefit was found for cognition, agitation, depression,
or functional outcomes.
Slow-Wave Sleep Augmentation
Slow-wave sleep (SWS) represents the central electrophysio-
logical element of the sleep-dependent recovery process, as
well as being implicated in sleep-dependent memory
Table 2 Behavioral sleep therapy
measures Measure Description
Stimulus control Avoidance of bed other than for sleeping or sex; leaving bed if unable to sleep
Sleep restriction Limiting the sleep period to promote consolidated sleep
Sleep hygiene Regular bed/wake and meal times, limited daytime napping, optimization of bedroom
temperature/light/noise, avoidance of nicotine/caffeine/alcohol < 4 h before bed, regular
physical exercise > 4 h before bedtime
Cognitive therapy Altering deleterious psychological response to poor sleep
Relaxation
techniques
Including meditation, guided imagery, and progressive muscular relaxation
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consolidation [32], age-related changes in cognition [201],
and glymphatic clearance of neurotoxic waste [23, 202]. It is
consistently impaired across the spectrum of neurodegenera-
tion [35]. As a result, the development of neurophysiological
stimulation techniques that augment SWS,most notably trans-
cranial direct-current stimulation (TDCS) and acoustic stimu-
lation applied during sleep, is a further important emerging
frontier in the field of sleep therapies in neurodegeneration.
The ability of such techniques to augment the slow oscilla-
tions (SOs) underpinning SWS has been demonstrated consis-
tently and robustly in numerous blinded cross-over sham/stim
paradigm studies [203]. While it may seem improbable that
pulses of sound alone would have such an effect, it is possible
and thought to be mediated by an interaction between the
nonlemniscal acoustic pathway and diffuse thalamocortical
projections during sleep, wherein acoustic stimuli evoke a
widespread synchronous response, akin to a transient SO, in
order to mediate arousal to threat. Where the stimulus is at
threshold, it is able to induce SO activity without arousal [204].
Transcranial Direct-Current Stimulation
Augmentation of slow oscillation activity by TDCS has dem-
onstrated benefit to declarative memory in both young
[205–207] and older [208, 209] healthy participants, and in
both nocturnal [206] and nap [205, 207, 208] protocols. In
Cellini et al. [207], this was accompanied by an overall in-
crease in time spent in slow-wave sleep, and cognitive benefits
persisted at 48 h.
There have, however, been a number of negative studies
using this approach [210–212]. This discrepancy may relate to
the variability of the stimulation protocols applied, as well as
the timing and frequency of TDCS—all of which appears to
be critical to efficacy. For example,Marshall et al. [213] found
that theta-TDCS reduces slow oscillation activity and impairs
declarative memory while the stimulation protocol used in the
negative study by Eggert et al. [212] in fact induced a reduc-
tion in slow-wave sleep and increased wake time. By contrast,
Cellini et al. [207] found that stimulation during asynchronous
slow-wave sleep was more efficacious than that applied dur-
ing endogenous SO activity, and positive findings may have
related to the incorporation of such stimulation in their study.
Incongruent findings may also relate to the study population:
Koo et al. [214], for example, found that any cognitive bene-
fits of TDCS were only apparent when participants were strat-
ified according to higher baseline memory function.
Of note, two studies also evaluated the effect of sleep–
TDCS on mood, demonstrating a positive effect in both
healthy participants [205] and those with schizophrenia [215].
To date, only one study of TDCS in sleep has been conduct-
ed in a neurodegenerative cohort. This study [216], undertaken
during a nap protocol in sixteen participants withmild cognitive
impairment, demonstrated benefit to visual but not verbal or
visuospatial declarative memory at 30 min post awakening.
Acoustic Stimulation
Slow-wave augmentation by acoustic stimulation has likewise
demonstrated cognitive benefit in young [217–219], middle-
aged [220], and older healthy adults [221], in both nap [217]
and nocturnal [218–221] protocols, with benefits seen in ex-
ecutive function [220] as well as declarative memory
[217–219, 221]. In most cases, this was mediated through
tones of pink noise delivered by headphones, but more recent-
ly, bone conduction via a mastoid application has also been
implemented successfully [222].
Compellingly, the degree of cognitive enhancement correlat-
ed with the degree of slow-wave augmentation elicited in a num-
ber of these studies [218, 220, 221]. Response rates appear var-
iable; however, and in some studies, benefit was only seen when
nonresponders were excluded (35% participants) [220]. As with
TDCS, there are studies failing to demonstrate cognitive benefit
within the literature, but these have typically also failed to show
an overall increase in slow-wave activity following the interven-
tion [223, 224]. The precise stimulation protocol again appears
critical, but in comparison with TDCS, efficacy to boost slow-
wave activity and benefit to cognition appears greatest when
stimulation is phase-locked to the upstate of endogenous SOs
[218, 225, 226]: so-called closed loop stimulation.
There has to date been only one study of acoustic augmen-
tation of SWS in a neurodegenerative cohort [227].
Conducted in 2019, this nocturnal pilot study in nine patients
with amnestic mild cognitive impairment demonstrated highly
variable increases in slow-wave activity (1-30%), but promis-
ingly, improvement in declarative memory was demonstrated
in five of nine participants, and the degree of improvement
correlated with that of slow-wave activity augmentation.
The ease of delivery in a domiciliary setting, and its low side
effect profile, places acoustic stimulation at a significant practical
advantage over TDCS. Notably, a number of companies have
nowdeveloped headband devices delivering closed loop acoustic
stimulation, designed for use during sleep in the home setting
(e.g., Dreem2 headband, Phillips SmartSleep Deep Sleep
Headband), in some cases combined with delivery of personal-
ized behavioral measures guidance. It is worth noting, however,
that the cumulative effects of the long-term application of acous-
tic stimulation on cognition are not known: all studies evaluating
cognitive outcomes have, as yet, incorporated single-night and
immediate postsleep testing protocols only.
Concluding Remarks
Sleep dysfunction in neurodegenerative conditions merits pri-
oritization in clinical care: not only because it has the potential
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to significantly improve quality of life for patients and their
families, but also because there is mounting evidence to sug-
gest that it may also mitigate cognitive and affective symp-
toms and slow disease progression. Given the lack of therapies
that currently achieve this in neurodegeneration, this potential
should not be discounted.
In all cases, it is important that the approach to treating
sleep dysfunction in a patient with a neurodegenerative con-
dition begins with a comprehensive assessment of this aspect
of their condition, via targeted questions, objective scales, and
investigations, in order to identify preliminary contributory
factors (depression, pain, nocturia, medications, and caf-
feine/nicotine/alcohol use) and specific clinical sleep patholo-
gy (OSA, RLS, RBD, PLMD) where present. These should be
addressed with conservative measures and specific treatments
as outlined.
Only in the event of such measures failing to bring adequate
benefit should other interventions be considered. Of available
secondary measures, current evidence is most in favor of behav-
ioral measures alongside bright light therapy, although it is clear-
ly imperative that the practicality of such measures for an indi-
vidual’s circumstance is taken into account. Currently, the land-
scape of pharmacological options is largely unfavorable, with
deleterious effects likely to outweigh benefit for sedating agents
including antidepressants, antihistamines, and antipsychotics,
and a lack of cogent evidence suggesting significant benefit from
modafinil or melatonin. We would advocate that sedating agents
are only used where already mandated for concomitant affective
or behavioral symptoms, or in the event of failure of all other
measures. The overriding message is therefore that, as clinicians,
we should resist the engrained temptation to treat sleep dysfunc-
tion in neurodegeneration by add-on prescription and instead
take time to implement conservative measures and
nonpharmacological interventions that are more likely to bring
benefit. Nonetheless, the landscape of pharmacological options is
evolving, with both sodium oxybate and orexin antagonists
showing promise. Finally, the development of domiciliary de-
vices providing slow-wave sleep augmentation provides further
hope of efficacious intervention emerging in the near future.
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